Monday, 10 August 2020


Daiichi Sankyo & Gustave Roussy collaborate for oncology research

23 July 2020 | News

Program to focus on clinical and precision medicine research and potential combination strategies

Image Credit: shutterstock.com

Image Credit: shutterstock.com

Tokyo based Daiichi Sankyo Company Ltd. and France based Gustave Roussy recently announced a multi-year, multi-study research collaboration to enrich and further enable the development of DS-1062 and patritumab deruxtecan (U3-1402), two of Daiichi Sankyo’s lead DXd antibody-drug conjugates (ADCs), in lung and breast cancer.

The collaboration will focus on clinical and translational research, including potential combination strategies for DS-1062, a TROP2 directed DXd ADC, in patients with advanced non-small-cell lung cancer (NSCLC), and for patritumab deruxtecan, a HER3 directed DXd ADC, in patients with metastatic breast cancer.

Antoine Yver, MD, MSc, AIHP, ACCA Paris, Global Head, Oncology R&D, Daiichi Sankyo stated, “We look forward to engaging and collaborating with the deep expertise and cutting-edge oncology research capabilities of Gustave Roussy, the premier European Cancer Center, to further advance the clinical development of DS-1062 and patritumab deruxtecan.”


Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account




Podcast

 

Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls